NDAORALTABLET
Approved
May 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ADCIRCA (tadalafil) by Eli Lilly and Company is phosphodiesterase 5 inhibitors [moa]. Approved for erectile dysfunction, benign prostatic hyperplasia, pulmonary hypertension and 1 more indications. First approved in 2009.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADCIRCA (tadalafil) is an oral phosphodiesterase 5 inhibitor developed by Eli Lilly and approved in May 2009. It is indicated for pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise ability and for hypertension management. The drug works by inhibiting PDE5 to promote vasodilation and improve blood flow, addressing the pathophysiology of these cardiovascular conditions.
$0.0BPart D
Mechanism of Action
Phosphodiesterase 5 Inhibitors
Pharmacologic Class:
Phosphodiesterase 5 Inhibitor
Indications (4)
Worked on ADCIRCA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.